Cargando…

Lurbinectedin in small cell lung cancer

Few treatment options are available for patients with small cell lung cancer (SCLC) in progression after a first-line therapy. A novel therapeutic approach is represented by lurbinectedin, a synthetic derivative of trabectedin that works by inhibiting oncogenic transcription and promoting apoptosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manzo, Anna, Sforza, Vincenzo, Carillio, Guido, Palumbo, Giuliano, Montanino, Agnese, Sandomenico, Claudia, Costanzo, Raffaele, Esposito, Giovanna, Laudato, Francesca, Mercadante, Edoardo, La Manna, Carmine, Muto, Paolo, Totaro, Giuseppe, De Cecio, Rossella, Picone, Carmine, Piccirillo, Maria Carmela, Pascarella, Giacomo, Normanno, Nicola, Morabito, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469650/ https://www.ncbi.nlm.nih.gov/pubmed/36110944 http://dx.doi.org/10.3389/fonc.2022.932105

Ejemplares similares

RET Inhibitors in Non-Small-Cell Lung Cancer
por: Cascetta, Priscilla, et al.
Publicado: (2021)

Immunotherapy in Small Cell Lung Cancer
por: Esposito, Giovanna, et al.
Publicado: (2020)

Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
por: Palumbo, Giuliano, et al.
Publicado: (2020)

Angiogenesis Inhibitors in Small Cell Lung Cancer
por: Montanino, Agnese, et al.
Publicado: (2021)

BRAF Inhibitors in Non-Small Cell Lung Cancer
por: Sforza, Vincenzo, et al.
Publicado: (2022)

Angiogenesis Inhibitors in NSCLC
por: Manzo, Anna, et al.
Publicado: (2017)

Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion
por: Morabito, Alessandro, et al.
Publicado: (2022)

Surgery in Small-Cell Lung Cancer
por: Martucci, Nicola, et al.
Publicado: (2021)

Focus on Nintedanib in NSCLC and Other Tumors
por: Manzo, Anna, et al.
Publicado: (2016)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Lurbinectedin for small cell lung cancer
Publicado: (2021)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

Lurbinectedin-induced thrombocytopenia: the role of body surface area
por: Papachristos, Apostolos, et al.
Publicado: (2022)

Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma
por: Anobile, Dario P., et al.
Publicado: (2021)

Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls
por: Esposito Abate, Riziero, et al.
Publicado: (2020)

Immunotherapy Assessment: A New Paradigm for Radiologists
por: Granata, Vincenza, et al.
Publicado: (2023)

Promoters of ASCL1‐ and NEUROD1‐dependent genes are specific targets of lurbinectedin in SCLC cells
por: Costanzo, Federico, et al.
Publicado: (2022)

Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
por: Gros, Louis, et al.
Publicado: (2021)

ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer
por: Schultz, Christopher W, et al.
Publicado: (2023)

Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia
por: Aquila, Giorgio, et al.
Publicado: (2020)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Specific Effects of Trabectedin and Lurbinectedin on Human Macrophage Function and Fate—Novel Insights
por: Povo-Retana, Adrián, et al.
Publicado: (2020)

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer
por: Awada, A.H., et al.
Publicado: (2022)

Lurbinectedin improves macular edema in a case of central retinal vein occlusion()
por: Simona, Filippo, et al.
Publicado: (2022)

Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity
por: Povo-Retana, Adrián, et al.
Publicado: (2023)

Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer
por: Tummala, Tej, et al.
Publicado: (2023)

Multiple sclerosis - New treatment modalities
por: Totaro, Rocco, et al.
Publicado: (2015)

Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2020)

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
por: Fudio, Salvador, et al.
Publicado: (2020)

Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology
por: Pascarella, Giacomo, et al.
Publicado: (2019)

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
por: Kepp, Oliver, et al.
Publicado: (2020)

An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer
por: Patel, Shetal, et al.
Publicado: (2021)

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study
por: Fudio, Salvador, et al.
Publicado: (2023)

Imaging Assessment of Interval Metastasis from Melanoma
por: Simonetti, Igino, et al.
Publicado: (2022)

Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
por: Kristeleit, Rebecca, et al.
Publicado: (2021)

Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
por: Calvo, Emiliano, et al.
Publicado: (2022)

Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer
por: Bhamidipati, Deepak, et al.
Publicado: (2023)

Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
por: Hanvesakul, Raj, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8v03a7c0mqcj5b4folrtrljpbe